Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Jones Lang LaSalle Inc (JLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Jones Lang LaSalle Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224.04 (market cap $29.60B), while Jones Lang LaSalle Inc trades at $362.12 (market cap $16.72B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Jones Lang LaSalle Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | JLL | |
|---|---|---|
Market Cap | $29.60B | $16.72B |
Sector | Health | Real Estate |
52-Week High | $491.22 | $373.24 |
52-Week Low | $205.48 | $280.16 |
Enterprise Value | $27.56B | $19.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
JLL trades at $363.49, up 1.72% today, near its 52-week high. The stock exhibits bullish technical signals with a golden cross and strong momentum, supported by consistent earnings beats in recent quarters. Revenue grew to $26.12B in 2025, with net income margin improving to 3.64%. Analyst consensus is bullish with a $391.50 price target, and institutional holdings show confidence from firms like Bank of America.
Outlook remains positive driven by earnings growth and operational strength, but risks include economic sensitivity and competitive pressures. The stock offers upside to consensus targets, though valuation metrics like P/E of 17.43 require monitoring for sustainability amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →
